Cell Therapy Specialist at Stanford Hospital and Clinics, Finance Manager at Los Trancos County Water District
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
Stanford Hospital and Clinics - Stanford Hospital and Clinics since Feb 2012
Cell Therapy Specialist
Los Trancos County Water District since Jan 2008
Finance Manager
Stanford University School of Medicine - Stanford School of Medicine Jan 2010 - Jan 2012
Life Science Research Associate
Stanford University School of Medicine - Stanford Blood Center Apr 2009 - Nov 2009
Basic Life Science Research Associate
Genitope Corp May 2002 - Jul 2008
Sr. Scientist
Education:
Université de Paris VII 1988 - 1991
PH.D., Immunology
Illinois State University 1974 - 1978
BS, Medical Technology
Dan Denney - Redwood City CA, US Keri Marie Tate - Portola Valley CA, US Thomas P. Theriault - Palo Alto CA, US
Assignee:
Genitope Corporation - Redwood City CA
International Classification:
A61K 39/395 A61K 39/00
US Classification:
424155100, 424185100
Abstract:
The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same lymphoma cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.
Dan Denney - Redwood City CA, US Keri Tate - Portola Valley CA, US Thomas Theriault - Palo Alto CA, US
Assignee:
Genitope Corporation - Redwood City CA
International Classification:
A61K 39/395 C12Q 1/68 G01N 33/574 C12M 3/00
US Classification:
424155100, 435007230, 435287200, 435006000
Abstract:
The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same lymphoma cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.